Comparator: loratadine — Competitive Intelligence Brief

Comparator: loratadine (Comparator: loratadine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: H1-receptor antagonist (second-generation antihistamine). Area: Allergy/Immunology.

phase 3 H1-receptor antagonist (second-generation antihistamine) H1 histamine receptor Allergy/Immunology Small molecule

Target snapshot

Comparator: loratadine (Comparator: loratadine) — Organon and Co. Loratadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without significant central nervous system penetration.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comparator: loratadine TARGET	Comparator: loratadine	Organon and Co	phase 3	H1-receptor antagonist (second-generation antihistamine)	H1 histamine receptor
Diphenhydramine 5%	Diphenhydramine 5%	Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology	marketed	H1 receptor antagonist (first-generation antihistamine)	H1 histamine receptor
montelukast and cetirizine	montelukast and cetirizine	Medical University of Lodz	marketed	Leukotriene receptor antagonist and H1-receptor antagonist combination	CysLT1 receptor (montelukast); H1 histamine receptor (cetirizine)
alcaftadine 0.25% ophthalmic solution	alcaftadine 0.25% ophthalmic solution	Allergan	marketed	Selective H1-receptor antagonist	H1 histamine receptor
Fluticasone furoate and fexofenadine	Fluticasone furoate and fexofenadine	GlaxoSmithKline	marketed	Intranasal corticosteroid and antihistamine combination	Glucocorticoid receptor (fluticasone furoate); H1 histamine receptor (fexofenadine)
Benadryl demand	Benadryl demand	University of Pennsylvania	marketed	First-generation H1 antihistamine	H1 histamine receptor
diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	Montefiore Medical Center	marketed	Combination cold/cough/allergy remedy	H1 histamine receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); NMDA receptor and sigma-1 receptor (dextromethorphan)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (H1-receptor antagonist (second-generation antihistamine) class)

1. UCB Pharma · 5 drugs in this class
2. Organon and Co · 3 drugs in this class
3. Brian J Lipworth · 1 drug in this class
4. GlaxoSmithKline · 1 drug in this class
5. Goldman, Butterwick, Fitzpatrick and Groff · 1 drug in this class
6. HK inno.N Corporation · 1 drug in this class
7. AAADRS Clinical Research Center · 1 drug in this class
8. University Hospital, Grenoble · 1 drug in this class
9. Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona · 1 drug in this class